| abstract |
The present invention relates to: a method for producing CAR-M1 macrophages that express a chimeric antigen receptor, in vitro and in vivo, the method comprising a step of using a conjugate of a non-viral gene delivery system and a chimeric antigen receptor gene; CAR-M1 macrophages produced by the method; and use of the cells. The CAR-M1 macrophages of the present invention are produced in vivo by delivering genes encoding a chimeric antigen receptor and IFN―γ, specifically to macrophages in the body, and thus does not require steps of culturing and preparing an in-vitro cellular therapeutic agent, thus reducing the manufacturing costs of therapeutic agents. In addition, the CAR-M1 macrophages are a safer therapy since a non-viral vector is used, as compared to the production of CAR-M1 macrophages by gene delivery using a viral vector, and are a novel therapeutic candidate having the advantage of high anticancer efficiency for solid cancers, due to CAR-M1 macrophages in which intrinsic properties of macrophages infiltrating solid cancers and cancer cell phagocytosis are improved. |